Scholar Rock Holding Corp (SRRK) Return on Investment ROI from the second quarter of 2026 to second quarter of 2025 and for the year 2026, average high and low, overall ranking from Jun 30 2026 to Jun 30 2025 - CSIMarket
Scholar Rock Holding's ROI from its second quarter of 2026 to the second quarter of 2025 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Scholar Rock Holding's ROI in the second quarter of 2026?
Scholar Rock Holding Corp recorded a cumulative net loss of $-409 million during 12 months ending in the second quarter of 2026, resulting in a negative return on investment (ROI) of -99.51%.
Within the Healthcare sector 514 other companies had a higher return on investment. While return on investment, the total ranking has deteriorated compared to the first quarter of 2026 from 2271 to 4028.
Scholar Rock, a biopharmaceutical company listed on NASDAQ as SRRK, has reported significant progress in its development of apitegromab, a pioneering therapy for spinal muscular atrophy (SMA). The company announced that their Phase 3 SAPPHIRE clinical trial (NCT05156320) has successfully met its primary endpoint, showing promising efficacy and safety for the treatment of SMA, a debilitating genetic disorder that affects muscle strength and motor function. Phase 3 SAPPHIRE Study Results Conducted by Scholar Rock in collaboration with multiple clinical centers, the Phase 3 SAPPHIRE trial was a randomized, placebo-controlled study evaluating the effects of apitegromab, an investigational muscle-targeted therapy. Apitegromab is designed to modulate the activity of myostatin, a protein growth factor that inhibits muscle growth, making it a potential game-changer for SMA patients who experience progressive muscle wasting.
Scholar Rock’s Recent Inducement Grants Questioned Amidst Financial Struggles By In a recent announcement, late-stage biopharmaceutical company Scholar Rock (NASDAQ: SRRK) revealed that it granted inducement equity awards to six newly hired employees, covering a total of 201,469 shares of its common stock. This move comes at a time when the company’s financial status raises concerns, with a cumulative net loss of $-159 million in the twelve months ending in the third quarter of 2023. Scholar Rock s negative return on investment (ROI) of -60.05% only adds to the growing apprehension surrounding the firm s stability. The inducement grants provided to new employees are reported to be under the Nasdaq Listing Rule 5635(c)(4). These grants are typically offered to attract and incentivize talented individuals to join a company. While they can be advantageous in attracting top talent, critics argue that such grants can also be indicative of underlying financial struggles in companies.
In a recent announcement, Scholar Rock, a pioneering biopharmaceutical company focused on innovative treatments for spinal muscular atrophy (SMA), cardiometabolic disorders, and other serious diseases, revealed the addition of Katie Peng to its Board of Directors and the promotion of Mo Qatanani, Ph.D., as Chief Scientific Officer. These developments have significant implications for the company s future and prospects in the biopharmaceutical industry. Katie Peng s appointment to Scholar Rock s Board of Directors brings fresh expertise and perspectives as the company navigates the challenges of developing cutting-edge treatments. Peng s wealth of experience in the biotech industry will contribute to the strategic decision-making process, potentially leading to novel approaches in tackling SMA, cardiometabolic disorders, and other serious diseases. Furthermore, her addition may enhance Scholar Rock s access to influential networks, augmenting partnerships and collaborations.
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
